Retransplantation for recurrent hepatitis C virus (HCV) has been evaluated in small series.
In this study, investigators from the United States evaluated patients who underwent transplantation for HCV-related cirrhosis and retransplantation >90 days later for recurrent HCV.
They compared these patients with a simultaneous cohort of patients who did not have HCV infection, but who underwent retransplantation >90 days after primary transplantation.
Overall, 42 patients underwent retransplantation for recurrent HCV.
|Median survival after retransplantation = 12.9 months.|
They had a median survival of 12.9 months after retransplantation.
The team found that 48% of patients were dead at 6 months, and that 65% of these deaths were due to sepsis.
Creatinine level, platelet count, prothrombin time, alkaline phosphatase level, gamma-glutamyltransferase level, and donor age all correlated with survival after retransplantation.
However, the team identified prothrombin time and donor age as predictors of survival on multivariate analysis.
The investigators found that patients undergoing retransplantation for recurrent HCV had a significantly shorter median survival than patients undergoing retransplantation for other reasons.
Dr Sasan Roayaie's team concluded, "Median survival after liver retransplantation for recurrent HCV is significantly shorter than after retransplantation for other causes of late graft loss".
"Most deaths occur in the first 6 months and are due to sepsis".
"Candidates for retransplantation with a preoperative prothrombin time <16 seconds and those receiving grafts from donors younger than 60 years can expect a significantly longer median survival after retransplantation".